Karim Fizazi, Arun Azad, Nobuaki Matsubara, Joan Carles, Andre P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Eric Voog, Robert Jones Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschaebitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Matko Kalac, Douglas Laird, Dana A. Kennedy, Neeraj Agarwal. "Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line (1L) treatment in patients (pts) with homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.5_suppl.lba141